Cartesian Therapeutics (RNAC) Intangibles (2023 - 2026)

Cartesian Therapeutics (RNAC) has 4 years of Intangibles data on file, last reported at $93.9 million in Q1 2026.

• Intangibles for Q1 2026 came in at $93.9 million, down 37.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $93.9 million (down 37.65% YoY), and the FY2025 annual result was $93.9 million, down 37.65% from the prior year.
• Intangibles steadied at $93.9 million in Q1 2026 per RNAC's latest filing, from $93.9 million in the prior quarter.
• Over five years, Intangibles peaked at $150.6 million in Q4 2023 and troughed at $93.9 million in Q4 2025.
• A 4-year average of $139.3 million and a median of $150.6 million in 2023 frame the typical range for Intangibles.
• The sharpest annual moves came in 2024 and 2025: Intangibles changed 0.0% in 2024, then tumbled 37.65% in 2025.
• A 4-year view of Intangibles shows it stood at $150.6 million in 2023, then changed by 0.0% to $150.6 million in 2024, then plunged by 37.65% to $93.9 million in 2025, then changed by 0.0% to $93.9 million in 2026.
• Business Quant data shows RNAC's Intangibles at $93.9 million in Q1 2026, $93.9 million in Q4 2025, and $150.6 million in Q3 2025.